Diane Trieu, MD
MOHS-Micrographic Surgery · Harvey, LANPI 1376710913
Payments from drug & device makers
Across 747 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sanofi$2K
- Johnson & Johnson$2K
- Lilly USA, LLC$1K
- UCB, Inc.$1K
- Pfizer$1K
- plus $6K from 31 others
What the payments were for
- Food & beverage$14,45996%
- Education$6574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 137 | $2,240 |
| Sanofi | 97 | $1,964 |
| Johnson & Johnson(2 entities) | 62 | $1,652 |
| Lilly USA, LLC | 53 | $1,150 |
| UCB, Inc. | 55 | $1,115 |
| Pfizer | 50 | $1,048 |
| Regeneron Healthcare Solutions, Inc. | 35 | $815 |
| Amgen | 44 | $754 |
| Incyte Corporation | 25 | $496 |
| Novartis | 22 | $435 |
| E.r. Squibb & Sons, L.L.C. | 23 | $418 |
| Galderma Laboratories, L.p. | 28 | $392 |
| LEO Pharma Inc. | 20 | $387 |
| Biofrontera Inc. | 25 | $360 |
| Sanofi-aventis U.S. LLC | 3 | $252 |
| Arcutis Biotherapeutics, Inc. | 8 | $197 |
| Revance Therapeutics, Inc. | 2 | $174 |
| Boehringer Ingelheim | 8 | $163 |
| Merz North America, Inc. | 4 | $147 |
| Convatec Inc. | 7 | $146 |
| Organon | 6 | $97 |
| Organogenesis Inc. | 5 | $92 |
| Almirall LLC | 3 | $77 |
| Dermavant Sciences, Inc. | 3 | $71 |
| Kerecis Limited | 3 | $70 |
| Botanix SB Inc | 3 | $67 |
| Verrica Pharmaceuticals Inc. | 2 | $51 |
| Elekta, Inc. | 1 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Mayne Pharma Commercial LLC | 3 | $45 |
| Journey Medical Corporation | 2 | $41 |
| Bioventus LLC | 1 | $28 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Acelrx Pharmaceuticals, Inc. | 1 | $15 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few mohs-micrographic surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 28 | $391,143 |
| Dupixent PenDupilumab | 74 | $276,910 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $263,474 |
| Humira(Cf) PenAdalimumab | 23 | $251,439 |
| Humira PenAdalimumab | 14 | $199,648 |
| TremfyaGuselkumab | 11 | $153,877 |
| Enbrel SureclickEtanercept | 11 | $80,880 |
| OtezlaApremilast | 13 | $62,356 |
| EucrisaCrisaborole | 19 | $17,900 |
| EnstilarCalcipotriene/Betamethasone | 13 | $17,825 |
| Pimecrolimus | 43 | $9,203 |
| Doxycycline Hyclate | 502 | $7,344 |
| Clobetasol Propionate | 153 | $4,839 |
| Ketoconazole | 331 | $4,078 |
| Ammonium Lactate | 100 | $2,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,652 | $153,87711 claims |
| AmgenOtezla | $754 | $62,35613 claims |
| PfizerEucrisa | $1,048 | $17,90019 claims |
| LEO Pharma Inc.Enstilar | $387 | $17,82513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few mohs-micrographic surgery providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other mohs-micrographic surgery in Harvey
- Rhonda BaldoneCovington$218K
- Keith LeblancMetairie$41K
- Rachel ReinaCovington$5K
- John ChapmanLafayette$5K
- Caitlin RobinsonMonroe$2K
- Eric FinleyMetairie$1K
- Zeena Al DujailiNew Orleans$1K
- Lee MillerLake Charles$614
- Randall RougelotMetairie$458
- Surget CoxMandeville$455
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.